IGF-1 LR3 is strictly for laboratory research and is commonly employed in the following investigational areas:

Mammalian Cell Culture & Stem Cell Maintenance

IGF-1 LR3 is extensively utilized as a highly potent supplement in serum-free media formulations for pluripotent stem cells, mesenchymal stem cells, and recombinant protein-producing cell lines (such as CHO cells). Researchers employ this peptide to maximize cellular survival, maintain undifferentiated states, and enhance cell density without the interference of endogenous binding proteins secreted by the cultured cells.

Myogenesis & Tissue Regeneration Models

In experimental models of tissue injury or mechanical overload, IGF-1 LR3 is used to study the autocrine and paracrine pathways governing cellular repair. Assays focus on quantifying the dose-dependent stimulation of skeletal myoblast proliferation, satellite cell activation, and the preservation of lean tissue mass independent of the systemic growth hormone axis.

Metabolic & Somatotropic Assays

Because it bypasses IGFBP regulation, IGF-1 LR3 serves as a precise chemical probe to isolate the direct effects of IGF-1R activation on cellular metabolism. Researchers investigate its impact on glucose uptake, amino acid transport, and the downstream modulation of endogenous growth hormone and insulin secretion.

Pathway / Mechanistic Context

The primary mechanism of action for IGF-1 LR3 in research settings revolves around the uninhibited, targeted activation of the IGF-1 receptor.

• Receptor Activation: IGF-1 LR3 binds to the extracellular α-subunits of the IGF-1R, inducing a conformational change that triggers the autophosphorylation of tyrosine residues on the intracellular β-subunits.
• Signal Transduction: This phosphorylation event recruits adapter proteins (like IRS-1), subsequently activating two primary intracellular cascades: the Phosphoinositide 3-kinase (PI3K)/AKT pathway and the Ras-Mitogen-Activated Protein Kinase (MAPK/ERK) pathway.
• Resulting Flux: Activation of the PI3K/AKT pathway predominantly inhibits cellular apoptosis and promotes protein synthesis, while the MAPK/ERK cascade drives potent mitogenic signals, prompting rapid cellular division and proliferation.

Preclinical Research Summary

Published preclinical literature documents investigations of IGF-1 LR3 across multiple experimental models:

• In Vitro Potency: Studies utilizing human embryonic stem cells (hESCs) and various mammalian cell lines consistently demonstrate that IGF-1 LR3 achieves equivalent or superior mitogenic stimulation at significantly lower concentrations than native IGF-1 or insulin due to its evasion of IGFBPs.
• Fetal Organogenesis: In vivo models involving intrafetal infusion in sheep reveal that targeted administration of IGF-1 LR3 successfully increases specific organ weights (e.g., heart, spleen) and drastically increases skeletal muscle myoblast proliferation.
• Metabolic Reprogramming: Data from metabolic assays indicate that sustained exposure to IGF-1 LR3 alters cellular nutrient utilization, efficiently driving amino acid uptake and glucose transport to support hyperplastic tissue expansion.

Form & Analytical Testing

This material is produced via robust chemical synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain compound integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Werner, H. (2023). The IGF1 Signaling Pathway: From Basic Concepts to Therapeutic Opportunities. International Journal of Molecular Sciences, 24(19), 14882. https://doi.org/10.3390/ijms241914882
• Stremming, J., et al. (2021). IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus. American Journal of Physiology-Endocrinology and Metabolism, 320(3), E527-E538. https://doi.org/10.1152/ajpendo.00453.2020
• Laron, Z. (2001). Insulin-like growth factor 1 (IGF-1): a growth hormone. Molecular Pathology, 54(5), 311-316. https://doi.org/10.1136/mp.54.5.311
• Kelly, A. C., et al. (2024). IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. American Journal of Physiology-Endocrinology and Metabolism, 326(3), E359-E370. https://doi.org/10.1152/ajpendo.00259.2024

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.